Recombinant Antibodies for GPCRs: A Challenge to the Community

A reagent gap that holds back the biology

GPCR activity is targeted by one-third of all FDA-approved drugs. Yet much remains to be learned about how these 800-plus receptors are expressed and how they function in living systems. Part of the gap is biology. Multipass transmembrane proteins are genuinely difficult targets. Part of the gap is the reagents. Reliable antibodies for human GPCRs are scarce, and without them, basic questions about expression and physiological function stay out of reach.

Producing specific antibodies for human GPCRs is a formidable job. Expression levels in common cell lines are often low. Identifying an immunoreactive antigen sequence that is specific for a single receptor and detectable across applications is difficult on its own. The literature often disagrees on which antibodies actually work. Proving specificity for the intended GPCR is rarely straightforward.

GeneTex is tackling that problem with a high-throughput recombinant antibody platform paired with enhanced validation strategies. The approach has already generated more than 300 recombinant monoclonal antibodies against almost 200 human GPCRs, and the catalog keeps growing.

Inside the platform

The production workflow is built to detect promising clones early and to hold specificity, scalability, and consistency steady once those clones are selected. Dr. Ball will walk through how the recombinant platform was built, what it takes to produce specific antibodies against multipass transmembrane targets including GPCRs at scale, and how the workflow handles the realities of low endogenous expression and tight specificity requirements.

Validation that earns the catalog its place

Every antibody is characterized through a prioritized validation set: CRISPR-based knockout and knockdown protocols, endogenous expression detection, cell fractionation, comparable antibody testing, and application-specific testing. When feasible, GeneTex uses VirDTM-GPCR arrays (CDI Labs, Mayagüez, PR), which present a nearly comprehensive library of human non-olfactory GPCRs individually expressed on herpes simplex virion envelopes for cross-reactivity screening. Dr. Ball will walk through each, explain why KO/KD testing is prioritized, and show how the validation data is shared with researchers.

The challenge: test them in your lab

This is the goal of the Dr. GPCR x GeneTex partnership. GeneTex is offering free samples of the recombinant antibodies to GPCR researchers in exchange for structured feedback, positive or negative. As Dr. Ball puts it in his own words, the primary goal is to get these reagents tested and evaluated by GPCR researchers. That is how a catalog earns the trust of the community, and how the community ends up with reagents it can actually rely on. Dr. Ball will explain how the challenge works, who it is for, and how to request samples.